We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Bond Kinetics Underlie von Willebrand's Disease

By Biotechdaily staff writers
Posted on 08 Jul 2002
A study has shown that the exceptional persistence of temporary chemical bonds between blood platelets and the von Willebrand factor (vWF) clotting protein underlies the bleeding disorder known as type IIb von Willebrand's disease. More...
The results, published in the July 2002 issue of Biophysical Journal, suggest that the disease occurs because a defective form of vWF allows vWF-platelet complexes to last longer than they should.

Until recently it was thought that substitution of one amino acid in defective vWF caused a conformational change that stabilized the bond between the protein and platelets. The findings of the current study support a different explanation, however. Investigators from the Washington University School of Medicine (St. Louis, MO, USA) found that bond kinetics, the rate at which chemical bonds form and dissociate, rather than a conformational change, is responsible.

"This is the first time that a naturally occurring disease has been linked to an alteration in the kinetic properties of a chemical bond,” explained study leader Dr. Thomas G. Diacovo, assistant professor of pediatrics, pathology, and immunology. "The finding should give us a better understanding of how normal platelets function and of the delicate balance that exists between these blood-clotting elements. Disturb that balance, and the whole system falls apart.”

The importance of bond kinetics had previously been demonstrated for a family of proteins called selectins, which are involved in the recruiting of white blood cells to inflamed blood vessel walls. Working with platelets in the current study, the researchers found that in normal individuals a few transient bonds form between circulating platelets and vWF. In type IIb von Willebrand's disease, however, the bonds last significantly longer than normal. That extra time allows many additional bonds to form, which stabilizes the interaction.

"It is not just a brief touch-and-go,” said Dr. Diacovo. "Rather, one bond forms and before it breaks, two, three, and four more have formed.” As more bonds form, small aggregates of platelets and vWF develop. These aggregates are removed from the blood, which reduces the amount of vWF and the number of platelets in circulation. Consequently, people with von Willebrand's disease have a mild-to-moderate bleeding disorder. They bruise easily and simple nosebleeds can continue for several hours or days before finally healing.


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Industry experts gather at WHX Labs Dubai to discuss how leadership must adapt as AI and automation transform the laboratory (Photo courtesy of Shutterstock)

WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories

WHX Labs in Dubai (formerly Medlab Middle East), held at Dubai World Trade Centre (DWTC) from 10–13 February, brings together international experts to discuss the factors redefining laboratory leadership,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.